# Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

> **NCT05255523** · PHASE2 · UNKNOWN · sponsor: **Fujian Medical University Union Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** pyrotinib

## Key facts

- **NCT ID:** NCT05255523
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-20
- **Primary completion:** 2023-11-05
- **Final completion:** 2024-12-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05255523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05255523, "Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05255523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*